Benitec Biopharma Inc. (BNTC): Price and Financial Metrics
GET POWR RATINGS... FREE!
BNTC Stock Summary
- BNTC has a market capitalization of $17,569,134 -- more than approximately only 2.48% of US stocks.
- BNTC's price/sales ratio is 627.47; that's higher than the P/S ratio of 99.29% of US stocks.
- As for revenue growth, note that BNTC's revenue has grown -52.54% over the past 12 months; that beats the revenue growth of only 3.07% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Benitec Biopharma Inc, a group of peers worth examining would be IMV, SONN, LCTX, ZSAN, and INFI.
- Visit BNTC's SEC page to see the company's official filings. To visit the company's web site, go to www.benitec.com.
BNTC Valuation Summary
- In comparison to the median Healthcare stock, BNTC's EV/EBIT ratio is 107.85% lower, now standing at -2.3.
- BNTC's EV/EBIT ratio has moved up 1.6 over the prior 74 months.
- BNTC's price/sales ratio has moved up 288.2 over the prior 74 months.
Below are key valuation metrics over time for BNTC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BNTC | 2021-08-31 | 304.9 | 2.8 | -3.8 | -2.3 |
| BNTC | 2021-08-30 | 328.4 | 3.1 | -4.0 | -2.6 |
| BNTC | 2021-08-27 | 308.8 | 2.9 | -3.8 | -2.4 |
| BNTC | 2021-08-26 | 318.6 | 3.0 | -3.9 | -2.5 |
| BNTC | 2021-08-25 | 317.6 | 3.0 | -3.9 | -2.5 |
| BNTC | 2021-08-24 | 319.6 | 3.0 | -3.9 | -2.5 |
BNTC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BNTC has a Quality Grade of F, ranking ahead of 1.09% of graded US stocks.
- BNTC's asset turnover comes in at 0.004 -- ranking 417th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows BNTC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.004 | 1 | -36.612 |
| 2020-06-30 | 0.007 | 1 | -8.634 |
| 2019-06-30 | 0.718 | 1 | 2.070 |
| 2018-06-30 | 0.214 | 1 | -3.387 |
| 2017-06-30 | 0.521 | 1 | -2.375 |
| 2016-06-30 | 0.020 | 1 | -18.246 |
BNTC Price Target
For more insight on analysts targets of BNTC, see our BNTC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.00 | Average Broker Recommendation | 2 (Hold) |
BNTC Stock Price Chart Interactive Chart >
BNTC Price/Volume Stats
| Current price | $1.01 | 52-week high | $5.07 |
| Prev. close | $1.00 | 52-week low | $0.90 |
| Day low | $0.97 | Volume | 33,300 |
| Day high | $1.09 | Avg. volume | 25,261 |
| 50-day MA | $1.69 | Dividend yield | N/A |
| 200-day MA | $2.79 | Market Cap | 8.25M |
Benitec Biopharma Inc. (BNTC) Company Bio
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.
Latest BNTC News From Around the Web
Below are the latest news stories about Benitec Biopharma Inc that investors may wish to consider to help them evaluate BNTC as an investment opportunity.
Benitec Biopharma Discloses Q2 2022 Financial ResultsBenitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the financial results for its Fiscal Year Q2 ended December 31, 2021. The Company has filed its quarterly report on Form 10-Q for the quarter ended December 31, 2021, with the U.S. Securities and Exchange Commission. |
/C O R R E C T I O N from Source -- Norra Metals Corp./Norra Metals Corp. ("Norra" or the "Company") (TSXV: NORA) (Frankfurt: 1KO) (OTC: NRRMF) intends to complete a non-brokered private placement, on a best efforts basis, of up to 10,000,000 units (the "Units") with a 20% over-allotment option at a price of $0.065 per Unit for gross proceeds of up to $650,000 (the "Offering"). |
Norra Metals Announces Private Placement FinancingNorra Metals Corp. ("Norra" or the "Company") (TSXV: NORA) (Frankfurt: 1KO) (OTC: NRRMF) intends to complete a non-brokered private placement, on a best efforts basis, of up to 10,000,000 units (the "Units") with a 20% over-allotment option at a price of $0.065 per Unit for gross proceeds of up to $650,000 (the "Offering"). |
Steven Michael Oliveira Buys 10,553 Shares of Benitec Biopharma Inc. (NASDAQ:BNTC) StockBenitec Biopharma Inc. (NASDAQ:BNTC) major shareholder Steven Michael Oliveira acquired 10,553 shares of Benitec Biopharma stock in a transaction that occurred on Thursday, December 9th. The stock was bought at an average price of $3.04 per share, for a total transaction of $32,081.12. The transaction was disclosed in a document filed with the Securities & [] |
We're Keeping An Eye On Benitec Biopharma's (NASDAQ:BNTC) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
BNTC Price Returns
| 1-mo | -37.26% |
| 3-mo | -57.02% |
| 6-mo | -68.24% |
| 1-year | -78.56% |
| 3-year | -96.24% |
| 5-year | -97.07% |
| YTD | -61.45% |
| 2021 | -12.67% |
| 2020 | -60.78% |
| 2019 | -66.00% |
| 2018 | -49.32% |
| 2017 | 93.46% |
Continue Researching BNTC
Want to see what other sources are saying about Benitec Biopharma LTD's financials and stock price? Try the links below:Benitec Biopharma LTD (BNTC) Stock Price | Nasdaq
Benitec Biopharma LTD (BNTC) Stock Quote, History and News - Yahoo Finance
Benitec Biopharma LTD (BNTC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...